Steve Seedhouse, biotech research analyst at Cantor Fitzgerald, has over 10 years of experience in equity research at Citi, Stifel, BMO Capital Markets, and Raymond James. He was most recently Head of Biotech Research at Raymond James where he spent the prior 7 years before joining Cantor in March 2025. Steve has a PhD in Molecular Pharmacology from Roswell Park Cancer Institute and MSc in Medical Chemistry from University at Buffalo.